PROGRAM MENU

EDUCATIONAL PROGRAM

PRE-SUMMIT WORKSHOPS

SATELLITE SYMPOSIA


Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2026 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.


  Wed - Mar 18      Thu - Mar 19      Fri - Mar 20      Sat - Mar 21   

SATURDAY, MARCH 21

7:00 - 8:00 AM
SATELLITE SYMPOSIUM
DRIVING INNOVATION FORWARD IN HEMOPHILIA B WITH GENE THERAPY: CLINICAL CONVERSATIONS ON PROGRESS AND GUIDANCE ON PRACTICAL DELIVERY (PROVIDED BY PEERVIEW LIVE, SUPPORTED BY CSL BEHRING)
B113-114

To register and learn more, visit: PeerView. com/Portland26-Live For patients with hemophilia B who are accustomed to the demands of lifelong intravenous factor IX replacement therapy, advances with gene therapy represent a fundamental reimagining of what effective disease control could look like. However, numerous questions remain regarding the role of gene therapy within an expanding hemophilia treatment landscape and how to safely deliver care. Join PeerView for this CaseBook live symposium to hear our expert panel engage in dynamic case-based dialogue that illustrates the therapeutic impact of gene therapy in hemophilia B and offers care team clinicians strategies for implementing a collaborative, multimodal treatment model to overcome implementation barriers. Dont miss this opportunity to gain real-world insights on evidence-based, patient-centered approaches to gene therapy in hemophilia Bregister today to join us! Credits: CME: 1. 0 AMA PRA Category 1 CreditTM AAPA: 1 AAPA Category 1 CME credits IPCE: 1. 0 Interprofessional Continuing Education (IPCE) credit


7:00 - 1:00 PM
EVENT/OTHER
REGISTRATION
Oregon Ballroom Lobby

8:15 - 9:45 AM
HEMOSTASIS / BASIC SCIENCE
DIFFERENT PERSPECTIVES OF GENETICS IN HEMOSTASIS
Chair/Organizer: Dawn Rotellini, Jordan Shavit
Oregon Ballroom 201


8:15
GENE MODIFIERS OF BLEEDING DISORDERS USING ZEBRAFISH (BASIC/TRANSLATIONAL PERSPECTIVE)
JORDAN SHAVIT.


8:45
GENE MODIFIERS OF RARE BLEEDING DISORDERS (ATHN 10 STUDY, CLINICAL PERSPECTIVE)
DIANE NUGENT.


9:15
PATIENT ADVOCATE ON THE ROLE OF GENETIC TESTING IN THEIR DIAGNOSIS, TREATMENT, & QOL
SHELLYE HOROWITZ.

8:15 - 9:45 AM
LABORATORY
RARE BLEEDING DISORDERS
Chair/Organizer: Cathy Hayward, Bethany Samuelson Bannow
Oregon Ballroom 204


8:15
UTILITY AND COST-EFFECTIVENESS OF GENETIC TESTING IN DIAGNOSIS OF BLEEDING DISORDERS/BLEEDING OF UNKNOWN CAUSE
MEGAN CHAIGNEAU.


8:45
DIAGNOSING PLASMINOGEN DEFICIENCY - CLINICAL AND LABORATORY CONSIDERATIONS
AMY SHAPIRO.


9:15
PATIENT JOURNEYS TO DIAGNOSIS OF A RARE BLEEDING DISORDER
CAROLINE KRUSE.

8:15 - 9:45 AM
THROMBOSIS
THE CLOT THICKENS: NAVIGATING THROMBOSIS RISK IN CANCER PATIENTS
Chair/Organizer: Rushad Patell, Arthur Allen
Oregon Ballroom 203


8:15
ARTERIAL THROMBOSIS IN CANCER
A LEADER.


8:45
ANTICOAGULATING THE CANCER PATIENT WHO HIGHER RISK FOR BLEEDING (BRAIN TUMOR, METS, THROMBOCYTOPENIA)
KRISTEN SANFILLIPO.


9:15
THERAPEUTIC ADVANCES IN TREATING AND PREVENTING CA ASSOCIATED THROMBOSIS
MARC CARRIER.

9:45 - 10:30 AM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Exhibit Hall A


A3. VASCULAR WALL BIOLOGY, ENDOTHELIAL PROGENITOR CELLS AND PLATELET ADHESION


700
IMANIXIL-MEDIATED DISRUPTION OF LIPID TRAFFICKING IMPAIRS HEPATIC HEMOGLOBIN CLEARANCE IN SICKLE CELL DISEASE
AYYANAR SIVANANTHAM1, NANDHINE RAJASEKAR2, MARTA WOLOSOWICZ1, NICHOLAS SWENDROWSKI1, TIRTHADIPA PRADHAN-SUNDD2, 3. 1Thrombosis and Hemostasis Program, Versiti Blood Research Institute and Blood Center of Wisconsin, Milwaukee, WI, USA. 2Transfusion Medicine, Vascular Biology and Cell Therapy Program, Versiti Blood Research Institute, Milwaukee, WI, USA. 3Department of Cell Biology, Neurobiology and Anatomy, Medical college of Wisconsin, Milwaukee, WI, USA


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


701
EFFICACY AND SAFETY OF CAPLACIZUMAB IN THROMBOTIC THROMBOCYTOPENIC PURPURA: A SYSTEMATIC REVIEW AND META-ANALYSIS
URSULA MEDEIROS ARAUJO DE MATOS1, PEDRO LUIZ LAGE BODOUR DANIELIAN2, RITIKA VANKINA3. 1Internal Medicine Department, University of Connecticut, Farmington, CT, USA. 2Harvard T. H. Chan School of Public Health, Boston, MA, USA. 3Hematology Oncology Department, University of Connecticut, Farmington, CT, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


702
INNATE IMMUNE CELL ACTIVATION IS ASSOCIATED WITH ANAPHYLACTIC OUTCOMES IN FACTOR IX EXPOSED HEMOPHILIA B MICE
HUONG CHAU, ELIZABETH YORK, ATHENA S ARAGON, VERONICA GONZALEZ-PENA, CHARLES GAWAD, GLAIVY BATSULI. Stanford University, Palo Alto, CA, USA


703
DETERMINATION OF REGV131-LNP1265-DERIVED HUMAN FACTOR IX ACTIVITY USING ONE-STAGE CLOTTING AND CHROMOGENIC SUBSTRATE ASSAYS: RESULTS FROM A COMPARATIVE FIELD STUDY
KAROLINE A. MEAGHER1, ROBERT J. DURSO1, KEHDIH LAI1, DAN CHALOTHORN1, NATALIE NIEPOTH1, SHANE MCCARTHY1, SARA HAMON1, DAVID E. GUTSTEIN1, MEAGAN P. OA1, STEFAN TIEFENBACHER2, WILLIAM PICKERING2, MARY ROBINSON3, MICHAEL E. BURCZYNSKI1. 1Regeneron Pharmaceuticals, Inc, Tarrytown, NJ, USA. 2Colorado Coagulation, Laboratory Corporation of America HoldingsAr, Englewood, CO, USA. 3Colorado Coagulation, Laboratory Corporation of America HoldingsAr (at the time of the study), Englewood, CO, USA


704
DETECTION OF CONTACT PATHWAY BIOMARKERS IN ECMO PATIENT PLASMA TO ASSESS DEVICE-ASSOCIATED THROMBOSIS
JENNY SI HAN WANG1, ROSEMARY B. FALAMA2, HELEN H. VU3, CRISTINA PUY1, OWEN J. T. MCCARTY1, JOSEPH J. SHATZEL1, 3, 4. 1Department of biomedical engineering, Portland, OR, USA. 2Department of medicine, Portland, OR, USA. 3Knight Cancer Institute, Portland, OR, USA. 4Division of Hematology and Medical Oncology, Portland, OR, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


705
VENOUS THROMBOEMBOLISM AND BLEEDING IN ADVANCED MELANOMA: A PROPENSITY-MATCHED COHORT ANALYSIS COMPARING FIRST-LINE IMMUNOTHERAPY AND TARGETED THERAPY
FURKAN BAHAR1, LAUREN OA2, SORAVIS OSATAPHAN2, REED DREWS2, RUSHAD PATELL2. 1Department of Internal Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA. 2Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA


706
OUTCOMES BY DOSE ESCALATION CRITERIA IN PARTICIPANTS WITH HEMOPHILIA A OR B WITHOUT INHIBITORS RECEIVING MARSTACIMAB IN THE BASIS TRIAL
LAURENT FRENZEL1, TRAVIS GOULD2, PENGLING SUN3, ANDREW PALLADINO4, OLIVER GLASS3. 1Department of Haematology, Hemophilia Care and Research, Necker Hospital, Institut Imagine, Paris, France. 2Pfizer Inc, New York, NY, USA. 3Pfizer Inc, Cambridge, MA, USA. 4Pfizer Inc, Collegeville, PA, USA


707
SAFETY AND EFFICACY OF PDVWF/FVIII 1:1 PROPHYLAXIS IN CHILDREN UNDER 6 YEARS WITH SEVERE VWD: RESULTS FROM THE WIL-33 STUDY
AKSHAT JAIN1, CINDY LEISSINGER2, VLADIMIR VDOVIN3, PAVEL ZHARKOV4, LEONID DUBEY5, VALENTIN ACUREA6, ZORICA TRAJKOVA ANTEVSKA7, ESTER ZAPOTOCKA8, BOHUMASR BLAA¾EK9, SUSAN HALIMEH10, AMANDA RODRIGUEZ11, TARJA-ELINA WEISZ12, CRISTINA SOLOMON13, ROBERT F. SIDONIO JR14. 1Medical Director Hemophilia Treatment Center, Loma Linda University School of Medicine, Loma Linda, CA, USA. 2Tulane University, New Orleans, LA, USA. 3Morozovskaya Childrena, Moscow, Russia. 4Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia. 5Communal Institution of Lviv Regional Council, Western Ukrainian Specialized Childrena, Lviv, Ukrenia. 6IMSP Mother and Child Institute, ChiE, Moldova. 7ERASE Zorica Trajkova Antevska, PHI University Clinic for Child Diseases, Skopje, Moldova. 8Department of Pediatric Hematology and Oncology, University Hospital Motol and Second Faculty of Medicine, Charles University, Prague, Czech Republic. 9University Hospital Ostrava, Ostrava, Czech Republic. 10Gerinnungszentrum Rhein Ruhr, Duisburg, Germany. 11Octapharma US, Paramus, NJ, USA. 12Octapharma Pharmazeutika Produktionsgesellschaft m. b. H, Vienna, Austria. 13Octapharma AG, Clinical Research and Development and Clinical Operations Haematology, Lachen, Switzerland. 14Professor of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA


708
EVALUATING PEN-INJECTOR HANDLING AND PROS IN PATIENTS SWITCHING FROM EMICIZUMAB TO MIM8 IN FRONTIER5
JOHNNY MAHLANGU1, SANJAY AHUJA2, ERIN COCKRELL3, VASCTOR JIMACNEZ-YUSTE4, MICHELE SCHIAVULLI5, AMALIE RHODE HACGH NIELSEN6, CAMILA MARTINS MAZINI TAVARES6, EMILY WATERS7, CACDRIC HERMANS8, DAN JOHNSON7. 1Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 2Indiana Hemophilia a Thrombosis Center, Innovative Hematology, Indianapolis, IN, USA. 3Pediatric Hematology Oncology, Saint Josepha, Tampa, FL, USA. 4Hematology Department, La Paz University Hospital, Hospital La Paz Institute for Health Research, Universidad AutA³noma Madrid, Madrid, Spain. 5Santobono-Pausilipon, Childrena, Naples, Italy. 6Novo Nordisk A/S, SAcborg, Denmark. 7Novo Nordisk Inc, Plainsboro, NJ, USA. 8Division of Hematology, Cliniques universitaires Saint-Luc, UniversitAc catholique de Louvain (UCLouvain), Brussels, Belgium


709
PERFORMANCE EVALUATION, PRECISION AND METHOD COMPARISON OF A NOVEL AUTOMATED COAGULATION ANALYZER
GABRIELLE PEARL, LISA MEADOWS, VICKIE SIMMONS, MARY KNIGHTEN, LASHANTA BRICE, PAUL RILEY. Diagnostica Stago, Inc, Parsippany, NJ, USA


710
RURIOCTOCOG ALFA PEGOL USE IN IMMUNE TOLERANCE INDUCTION: AN ANALYSIS OF A PHASE 3 STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIA A
ROBERT F. SIDONIO, JR. 1, FLORA PEYVANDI2, 3, RACHEL S. BERCOVITZ4, SEOH LENG YEOH5, ZULAIHA MUDA6, PHU QUOC LE7, VEERLE MONDELAERS8, JIAAN-DER WANG9, RASHID KAZMI10, BA¼LENT ZA¼LFIKAR11, JOAN GU12, SRILATHA TANGADA12. 1Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, USA. 2Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Fondazione IRCCS Caa, Milan, Italy. 3Department of Pathophysiology and Transplantation, UniversitAndegli Studi di Milano, Milan, Italy. 4Department of Pediatrics, Northwestern University Feinberg School of Medicine, and Division of Hematology, Oncology, Neuro-Oncology, and Stem Cell Transplant, Ann a Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA. 5Department of Pediatrics, Hospital Pulau Pinang, Penang, Malaysia. 6Paediatric Department, Hospital Tunku Azizah Women Children Hospital, Kuala Lumpur, Malaysia. 7HAcmato-Oncologie, HAapital Universitaire des Enfants Reine Fabiola, Brussels, Belgium. 8Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent University, Ghent, Belgium. 9Center for Rare Disease and Hemophilia, Taichung Veterans General Hospital, Taichung, Taiwan. 10University Hospital Southampton, Southampton, United Kingdom. 11Department of Paediatric Haematology/Oncology, Istanbul University Oncology Institute, Istanbul, Turkey. 12Takeda Development Center Americas, Inc, Cambridge, MA, USA


711
PHARMACOKINETICS OF PLASMINOGEN, HUMAN-TVMH IN SUBJECTS WITH PLASMINOGEN DEFICIENCY TYPE 1
KAREN THIBAUDEAU1, JOSEPH PARKER2, PIERRE CHELLE3, ANDREA EDGINTON3, AMY SHAPIRO4. 1Kedrion Biopharma Inc, Laval, QC, Canada. 2Kedrion Biopharma Inc, Fort Lee, NJ, USA. 3University of Waterloo, Waterloo, ON, Canada. 4Indiana Hemophilia a Thrombosis Center, Indianapolis, IN, USA


A7. PATHOPHYSIOLOGY OF THROMBOSIS


712
PROFILING OF EXTRACELLULAR VESICLES AND THROMBO-INFLAMMATORY BIOMARKERS IN PATIENTS WITH PULMONARY EMBOLISM
PRAKASHA KEMPAIAH1, MIRA NIGUDKAR1, MARTIN LUNDY1, FAHIKA SIDDIQUI1, CHONGYU ZHANG1, BULENT KANTARCIOGLU1, DEBRA HOPPENSTEADT1, JEANINE WALENGA1, THAO DOAN2, JAWED FAREED1, AMIR DARKI3, W. KEITH JONES 1. 1Loyola University Stritch School of Medicine, Chicago, IL, USA. 2AbbVie, North Chicago, Illinois, USA, Chicago, IL, USA. 3Division of Cardiovascular Disease and Department of Internal Medicine, Loyola University Chicago, Chicago, IL, USA


A8. ANTITHROMBOTIC THERAPY


713
MULTIMODAL DEEP LEARNING FOR PULMONARY EMBOLISM SCREENING USING CHEST X-RAY AND ELECTROCARDIOGRAM DATA
AWAN AFIAZ1, 2, STEPHEN SALERNO2, SOMIN M LEE3, ASHER MENDELSON4, BARRET RUSH5, MATTHEW SAMUEL5, MAX TANG6, TAKESHI TOHYAMA7, JENNIFER ZIEGLER8, LEO A CELI9, 10, 11, JEFFREY T LEEK1, 2, BARBARA LAM12. 1Department of Biostatistics, University of Washington, Seattle, WA, USA. 2Public Health Sciences, Biostatistics, Fred Hutchinson Cancer Center, Seattle, WA, USA. 3University of Toronto, Toronto, ON, Canada. 4Section of Critical Care, Department of Medicine, University of Manitoba, Winnipeg, MB, Canada. 5Massachusetts Institute of Technology, Cambridge, MA, USA. 6University of Waterloo, Waterloo, ON, Canada. 7Institute for Medical Engineering a Science, Massachusetts Institute of Technology, Cambridge, MA, USA. 8Department of Medicine, University of Manitoba, Winnipeg, MB, Canada. 9Laboratory for Computational Physiology, Massachusetts Institute of Technology, Cambridge, MA, USA. 10Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA. 11Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA. 12Division of Hematology/Oncology, Department of Medicine, Fred Hutchinson Cancer Center, Seattle, WA, USA


714
THE SENTINEL ROLE OF THE PATHOLOGIST IN DISTINGUISHING BIVALIRUDIN OVERDOSING FROM CONTAMINATION IN PEDIATRIC PATIENTS ON ECLS
VADIM KOSTOUSOV1, KAREN BRUZDOSKI1, JUN TERUYA1, 2, 3. 1Department of Pathology a Immunology, TCH, BCM, Houston, TX, USA. 2Department of Pediatrics, TCH, BCM, Houston, TX, USA. 3Department of Medicine, TCH, BCM, Houston, TX, USA


715
A SINGLE-CENTER ANALYSIS OF BIVALIRUDIN INFUSION RATES IN PEDIATRIC PATIENTS REQUIRING SYSTEMIC ANTICOAGULATION FOR TREATMENT OR PREVENTION OF THROMBOSIS.
JENNIFER PAK1, KRISTIN MAHER2, KIARA LIGHT1, KARYL KANADA2, NABIHA HUQ SAIFEE3, GAVIN ROACH2. 1Department of Pharmacy, Seattle Childrena, Seattle, WA, USA. 2Division of Hematology-Oncology, Seattle Childrena, Seattle, WA, USA. 3Department of Lab Medicine and Pathology, University of Washington, Seattle, WA, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


716
OPTIMIZING TRANSCUTANEOUS AURICULAR NEUROSTIMULATION THERAPY FOR HEAVY MENSTRUAL BLEEDING: AN OPEN LABEL TRIAL
CHRISTOPHER J. CZURA1, ANGELA C. WEYAND2, MAUREEN K. BALDWIN3, MICHAEL RECHT4, 5, CAROLINE BENNER1, KIMIKO HARADA1, BROOKE WADE1, MEGHAN LUELLEN1, MELANIE A. MCWADE1, ALEJANDRO COVALIN1, NAVID KHODAPARAST1. 1Spark Biomedical, Inc, Dallas, TX, USA. 2University of Michigan Medical School, Ann Arbor, MI, USA. 3Oregon Health Sciences University, Portland, OR, USA. 4Yale School of Medicine, New Haven, CT, USA


717
ANTICOAGULATION PRACTICES IN ANTIPHOSPHOLIPID SYNDROME: A RETROSPECTIVE CHART REVIEW
ANTHONY LIANG, ADAM CUKER, PARDIS NIAMI. Hospital of the University of Pennsylvania, Philadelphia, PA, USA


718
DEVELOPMENT OF A MULTIDISCIPLINARY PROGRAM FOR THE PREVENTION OF VENOUS THROMBOSIS IN AMBULATORY PATIENTS WITH CANCER
JOCELYN VEALS1, KENDRA PRASAD1, ANDREA CERVI1, 2. 1Schulich School of Medicine a Dentistry, London, ON, Canada. 2Department of Medical Oncology, Windsor Regional Cancer Center, Windsor, ON, Canada

10:30 - 11:30 AM
SHORT TALKS
SHORT TALKS - ADVANCES IN PLATELET DISORDERS: THERAPEUTICS, DIAGNOSTICS, AND CLINICAL MANAGEMENT
Chair/Organizer: Bethany Samuelson Bannow, Karen Flint
Oregon Ballroom 201


10:30
DISCREPANT RESULTS IN VON WILLEBRAND TESTING - AN ALGORITHMIC APPROACH TO ADDRESS HETEROPHILIC ANTIBODY INTERFERENCE IN THE INNOVANCEVWF GPIBM ACTIVITY ASSAY(THSNATRAVEL AWARDEE)
KAREN E. FLINT1, JEREMY D. WILLIAMS1, JOSHUA L. RHODES1, KENNETH D. FRIEDMAN2, ANDREA STAUM2, SANDRA L. HABERICHTER2, BAILEY HUTCHISON2, ANDREW PODD2, LORI LUCHTMAN-JONES1, 3. 1Hemostasis and Thrombosis Lab, Hematology Division, Cancer and Blood Diseases Institute, Cincinnati Childrena, Cincinnati, OH, USA. 2Diagnostic Laboratories, Versiti/Blood Center of Wisconsin, Milwaukee, WI, USA. 3Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA


10:42
UTILIZE SALINE CONTROL IN HEPARIN-INDUCED THROMBOCYTOPENIA FUNCTIONAL ASSAY TO IDENTIFY HEPARIN-INDEPENDENT ANTIBODIES (THSNATRAVEL AWARDEE)
JING JIN1, KRINABEN PATEL1, LU YANG2, JAMES ZEHNDER2. 1Special Coagulation, Stanford Health Care Palo Alto, CA, USA. 2Department of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA


10:54
REDUCTION IN CONCOMITANT THERAPY USE WITH RILZABRUTINIB AND SUSTAINED RESPONSE IN ADULTS WITH PERSISTENT/CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN THE PHASE 3 LUNA3 LONG-TERM EXTENSION (LTE) PERIOD
DAVID J. KUTER1, LEI ZHANG2, WALEED GHANIMA3, YOSHITAKA MIYAKAWA4, YU HU5, DAVID GA³MEZ-ALMAGUER6, MATIAS CORDOBA7, MAREK WARDA8, LARISSA MEGE9, MEREDITH C. FOSTER7, AHMED DAAK7, HOWARD A. LIEBMAN10, SANDHYA PANCH11. 1Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 2Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. 3A, Oslo, Norway. 4Department of Hematology, Saitama Medical University, Saitama, Japan. 5Wuhan Xie'he Hospital, Wuhan, China. 6Hospital Universitario Dr. JosAc Eleuterio GonzAilez, Monterrey, Mexico. 7Sanofi, Cambridge, MA, USA. 8Sanofi, Warsaw, Poland. 9Sanofi, Lyon, France. 10University of Southern California, Los Angeles, CA, USA. 11Fred Hutch, Fred Hutch, USA


11:06
THROMBOCYTOPENIA IN PREGNANCY: A 5-YEAR ANALYSIS OF CHARACTERISTICS AND PRACTICES FROM A SINGLE U. S. INSTITUTION
MACKENZIE LEMIEUX1, MING LIM2. 1Division of Internal Medicine, University of Utah, Salt Lake City, UT, USA. 22. Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA


11:18
RECOMBINANT VON WILLEBRAND FACTOR PROPHYLAXIS FOR SEVERE VON WILLEBRAND DISEASE: FINAL RESULTS FOCUSING ON ADULTS RECEIVING ONCE WEEKLY PROPHYLAXIS IN A PHASE 3B CONTINUATION STUDY
SOPHIE SUSEN1, FRANK W G LEEBEEK2, GIANCARLO CASTAMAN3, AMY L DUNN4, MARGARITA A TIMOFEEVA5, CAITLIN MONTCRIEFF6, MARIA WALIULLAH7, JINGMEI ZHANG7. 1University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France. 2Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands. 3Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy. 4Department of Hematology, Oncology, Bone Marrow Transplant and Apheresis, Nationwide Childrena, Columbus, OH, USA. 5Federal State Budgetary Scientific Institution, Kirov Scientific-Research Institute of Hematology and Blood Transfusion of Federal Medical and Biological Agency, Kirov, Russia. 6Takeda Pharmaceuticals U. S. A, Inc, Lexington, MA, USA. 7Takeda Development Center Americas, Inc, Cambridge, MA, USA


SHORT TALKS - COAGULATION SCIENCE AND VON WILLEBRAND FACTOR RESEARCH
Chair/Organizer: Samantha Carlson, Rebecca Risman
Oregon Ballroom 204


10:30
COMPARATIVE CLINICAL AND ECONOMIC EVALUATION OF ON-DEMAND VERSUS PROPHYLACTIC TREATMENT WITH PDVWF/FVIII 1:1 AND RECOMBINANT VWF IN ADULTS WITH TYPE 3 VON WILLEBRAND DISEASE IN THE UNITED STATES
ROBERT F SIDONIO JR1, NATHAN T CONNELL2, 3, 4, FERNANDO CORRALES-MEDINA5, CAROLINE MALCOLMSON6. 1Emory University School of Medicine, Atlanta, GA, USA. 2Boston Bleeding Disorders Center, Boston, MA, USA. 3Brigham and Women's Hospital, Boston, MA, USA. 4Harvard Medical School, Boston, MA, USA. 5University of Miami-Miller School of Medicine, Miami, FL, USA. 6University of Toronto, Toronto, ON, USA


10:42
FACTOR VIII PROTEIN MODIFICATIONS INFLUENCE THE IMMUNE RECOGNITION OF FVIIIFC-VWF-XTEN IN HEMOPHILIA A PATIENT SAMPLES (THSNATRAVEL AWARDEE)
ANA L. ALTAMIRANDA, MENGJIE J. KONG, HUONG CHAU, MAY CHIEN, ELIZABETH S. YORK, GLAIVY BATSULI. Stanford University, Palo Alto, CA, USA


10:54
COMPREHENSIVE COAGULATION PROFILING VIA ICOAGLAB IN PATIENTS TREATED WITH IMPELLA PUMPS
DANIEL HOARE, ANIKET JOSHI, ELI FOSTER, NATHANIEL HAI, ZIQIAN ZENG, SEEMANTINI NADKARNI. Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA


11:06
ACCELERATION OF INTERNAL LYSIS OF CONTRACTED CLOTS IS DRIVEN BY BUNDLING AND ALIGNMENT OF FIBRIN FIBERS (THSNATRAVEL AWARDEE)
REBECCA RISMAN1, 2, EVA IUNGBLUDT2, JOSHUA PACKER3, NATHAN HUDSON3, JOHN WEISEL1, VALERIE TUTWILER2. 1University of Pennsylvania, Philadelphia, PA, USA. 2Rutgers University, New Brunswick, NJ, USA. 3Eastern Carolina University, Greenville, NC, USA


11:18
VWF ACTIVITY GPIBM ASSAY KIT EVALUATION
JULIE I. TANGE1, DONG CHEN1, RAJIV K. PRUTHI1, 2, JULIANA PEREZ BOTERO1. 1Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA. 2Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA


SHORT TALKS - EMERGING THERAPEUTICS AND PROPHYLACTIC STRATEGIES IN COAGULATION DISORDER
Chair/Organizer: Rushad Patell, Gabe Fontaine
Oregon Ballroom 203

Not available for CE.



10:30
THE EFFECT OF FIBRINOGEN CONCENTRATE ON CLOT STRENGTH IN PATIENTS WITH CONGENITAL AND ACQUIRED FIBRINOGEN DEFICIENCY
SUCHITRA ACHARYA1, TRUPTI MEHTA SHAH2, CRISTINA SOLOMON3, SIGURD KNAUB3, CLAUDIA DJAMBAS KHAYAT4, ASHOK ROY5, FAHEEZ MOHAMED5, KEYVAN KARKOUTI6, JEANNIE CALLUM7, 8, TOSHKO LISSITCHKOV9, FLORA PEYVANDI10, 11. 1Northwell Health, New Hyde Park, NY, USA. 2Octapharma USA, Paramus, NJ, USA. 3Octapharma AG, Lachen, Switzerland. 4Hospital HAatel Dieu de France, Saint Joseph University, Beirut, Lebanon. 5Peritoneal Malignancy Institute, Basingstoke, United Kingdom. 6University of Toronto, Toronto, ON, Canada. 7Queena, Kingston, ON, Canada. 8Kingston Health Sciences Centre, Kingston, ON, Canada. 9Specialized Hospital for Active Treatment (SHAT) a, Sofia, Bulgaria. 10Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. 11UniversitAn degli Studi di Milano, Milan, Italy


10:42
SUBCUTANEOUS FOUR-WEEK DOSING OF THE NOVEL PROTEIN S ANTIBODY VGA039 DEMONSTRATES SAFETY AND CLINICALLY MEANINGFUL BLEED REDUCTION IN PATIENTS WITH VON WILLEBRAND DISEASE: PHASE 1/2 MULTI-DOSE STUDY RESULTS
NICOLETTA C. MACHIN1, SHRINATH KSHIRSAGAR2, ADAM GIERMASZ3, JOHNNY MAHLANGU4, GABRIELA YAMAGUTI-HAYAKAWA5, SAVITA RANGARAJAN6, GENEVIEVE MOYER7, CHRISTINE KEMPTON8, JANE MASON9, MICHELLE SHOLZBERG10, PAULA VILLAASA11, SANDIP PANICKER12, EILEEN K. SAWYER12, GARY PATOU12, BENJAMIN KIM12, ALLISON P. WHEELER13. 1Division of Classical Hematology, Department of Medicine, University of Pittsburgh and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA. 2Advanced Center for Oncology, Haematology a Rare Disorders, K. J. Somaiya Medical College a Research Center, Somaiya Ayurvihar, Mumbai, India. 3Division of Hematology/Oncology, Department of Medicine, University of California Davis, Sacramento, CA, USA. 4Haemophilia Comprehensive Care Centre, Charlotte Maxeke Johannesburg Hospital, University of the Witwatersrand, Johannesburg, South Africa. 5Hemocentro UNICAMP, University of Campinas, Campinas, Brazil. 6University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom. 7The University of Colorado Hemophilia and Thrombosis Center, Aurora, CO, USA. 8Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA. 9Queensland Haemophilia Centre, Department of Haematology and BMT, Royal Brisbane and Womena, Brisbane, Australia. 10Departments of Medicine, and Laboratory Medicine and Pathobiology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. 11Hospital das ClAsnicas, University of SApo Paulo, SApo Paulo, Brazil. 12Star Therapeutics, Inc, South San Francisco, CA, USA. 13Washington Center for Bleeding Disorders and Divisions of Pediatric Hematology/Oncology and Hematology/Oncology, University of Washington, Seattle, WA, USA


10:54
NXT007 PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITH OR WITHOUT FVIII INHIBITORS: A GLOBAL PHASE I/II MULTIPLE-ASCENDING-DOSE STUDY
MARIA ELISA MANCUSO1, 2, DAVIDE MATINO3, DAN HART4, FRANCISCO JOSAC LA³PEZ-JAIME5, CHRISTOPHE SCHMITT6, SANJAY AHUJA7, GIULIANA VENTRIGLIA6, ANNA KIIALAINEN6, LAURA YOUNG8, OLIVIER CATALANI6, MARK BELLETRUTTI9, TOM CHU 10, JERZY WINDYGA11, VASCTOR JIMACNEZ-YUSTE12, MICHAELA LEHLE6, JANICE M. STABER13. 1Humanitas University, Pieve Emanuele, Milan, Italy. 2Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. 3McMaster University, Hamilton, Ontario, Canada. 4Roche Products Ltd, Welwyn Garden City, United Kingdom. 5Hospital Universitario Regional de MAilaga, MAilaga, Spain. 6F. Hoffmann-La Roche Ltd, Basel, Switzerland. 7Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA. 8Auckland City Hospital, Auckland, New Zealand. 9Department of Pediatrics, University of British Colombia, Vancouver, British Columbia, Canada. 10Genentech, Inc, South San Francisco, CA, USA. 11Department of Hemostasis Disorders and Internal Medicine, Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine, Warsaw, Poland. 12La Paz University Hospital-IdiPAZ, AutA³noma University, Madrid, Spain. 13Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, IA, USA


11:06
EXPLORATORY ANALYSIS OF INTRINSIC PATHWAY-TRIGGERED THROMBIN GENERATION INHIBITION IN HEALTHY VOLUNTEERS AND PATIENTS POST-TOTAL KNEE ARTHROPLASTY WHO RECEIVED REGN9933A2 AND REGN7508CAT
KAROLINE A. MEAGHER, KUSHA MOHAMMADI, DATENG LI, ETHAN MARIN, AARON KITHCART, MEAGAN P. OA, SELIN SOMERSAN-KARAKAYA, KEHDIH LAI, DAN CHALOTHORN, ROBERT J. DURSO, MICHAEL E. BURCZYNSKI, POULABI BANERJEE, DAVID E. GUTSTEIN. Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA


11:18
FIRST-IN-HUMAN INVESTIGATION OF HMB-002: A SUBCUTANEOUS ANTIBODY FOR PROPHYLACTIC MANAGEMENT OF VON WILLEBRAND DISEASE
PRIYANKA RAHEJA1, AMY KNOTT2, ULRIKE LORCH3, HENRIK OSTERGAARD4, CATHERINE REA4. 1Department of Hematology, The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom. 2Bristol Haematology Unit, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom. 3Richmond Pharmacology, London, United Kingdom. 4Hemab Therapeutics, Cambridge, MA, USA

11:45 - 1:00 PM
PLENARY SESSION
THE ROLE OF ADVOCACY ORGANIZATIONS IN DRUG DEVELOPMENT, CT DESIGN, AND ADOPTION OF NEW KNOWLEDGE
Chair/Organizer: Anne Rose, Lana Castellucci
Oregon Ballroom 201


11:45
PATIENT ADVOCATE - NBDF
SAMANTHA CARLSON.


12:10
PATIENT ADVOCATE - PDSA
CAROLINE KRUSE.


12:35
CLINICIAN ADVOCATE
ROBERT SIDONIO.